drugset / Trial / NCT00530777

HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding

NCT00530777

RandomizedParallel-groupQuadruple-blindTreatment

Summary

In this study, we will determine whether treating pregnant and breastfeeding women co-infected with human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) with daily valacyclovir will reduce HIV-1 levels in plasma, genital, and breast milk and will decrease the risk of mother-to-child HIV-1 transmission (MTCT).

Timeline

Start
2008-04
Primary completion
2010-08
Completion
2010-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Valacyclovir Unknown 500 mg Oral